China Shineway Pharmaceutical's (HKG:2877) attributable profit fell 13% to 840.1 million yuan in 2024 from 969.5 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.
Earnings per share at the traditional Chinese medicine manufacturer fell to 1.11 yuan from 1.28 yuan in the previous year.
Revenue declined 16% to 3.78 billion yuan from 4.52 billion yuan a year earlier.
The company declared its first interim dividend of 0.36 yuan per share, payable May 20 to shareholders on record as of May 7.
Shares plunged 8% during Friday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.